CST3 and chronic kidney disease: The 2012 CKD-EPI formula for cystatin C revealed a prevalence of 19.5% (95% CI 18.7%–20.3%) and the combined formula for creatinine and cystatin C a prevalence of 13.2% (95% CI 12.5%–13.9%, Supplementary data, Table S1).